Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm’s lead selective inhibitor of nuclear export (SINE), Selinexor (KPT-330), in combination with “low-dose” (20 mg twice weekly) dexamethasone. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is 87.12%. On last trading day company shares ended up $47.12. Analysts mean target price for the company is $48.25. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average is 68.37%.
Yongye International, Inc (NASDAQ:YONG) announced that its stockholders voted in favor of the proposal to approve the agreement and plan of merger, dated as of September 23, 2013, as amended on April 9, 2014 , among the Company, Full Alliance International Limited, a British Virgin Islands company or “Holdco”, Yongye International Limited or Parent, a Cayman Islands exempted company with limited liability wholly-owned by Holdco, and Yongye International Merger Sub Limited, a Nevada corporation wholly-owned by Parent , providing for the merger of Merger Sub with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent. Yongye International, Inc (NASDAQ:YONG) shares fell -1.55% in last trading session and ended the day on $6.97. YONG Gross Margin is 61.20% and its return on assets is 18.70%. Yongye International, Inc (NASDAQ:YONG) quarterly performance is 23.58%.
Zacks reiterated their neutral rating on shares of Sysco Corp. (NYSE:SYY) in a research report sent to investors on Friday morning. The firm currently has a $39.00 price target on the stock. SYSCO Corporation (NYSE:SYY) shares moved down -1.94% in last trading session and was closed at $36.93, while trading in range of $36.56-$37.64. SYSCO Corporation (NYSE:SYY) year to date performance is 3.13%.
MFA Financial, Inc. (NYSE: MFA) announced that its Board of Directors has elected Laurie Goodman to its Board effective July 1, 2014. MFA Financial, Inc. (NYSE:MFA) ended the last trading day at $8.42. Company weekly volatility is calculated as 1.23% and price to cash ratio as 11.24. MFA Financial, Inc. (NYSE:MFA) showed a positive weekly performance of 0.24%.
Navidea Biopharmaceuticals, Inc. (AMEX: NAVB) announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) Injection indicated for guiding sentinel lymph node (SLN) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping in breast cancer and melanoma patients.Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) weekly performance is 0.58%. On last trading day company shares ended up $1.74. Analysts mean target price for the company is $2.81. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) distance from 50-day simple moving average is 7.01%.